Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / NLTX - Neoleukin announces preclinical data for immunotherapy candidate NL-201 shares fall

NLTX - Neoleukin announces preclinical data for immunotherapy candidate NL-201 shares fall

Neoleukin Therapeutics Inc.
Shares of Neoleukin Therapeutics (NASDAQ:NLTX) have lost 10.6% in morning trade on Wednesday, despite the company announcing presentation of preclinical data for its immunotherapy candidate NL-201 that highlighted its potential to treat hematologic cancers. The data was presented in a poster at the American Association of Cancer Research annual meeting. The data showed that NL-201 demonstrated antitumor activity in preclinical B-cell lymphoma models and synergized with radiation therapy to generate potent, antitumor immunity. If losses hold, NLTX stock is on track to post its seventh straight session of declines.

For further details see:

Neoleukin announces preclinical data for immunotherapy candidate NL-201, shares fall
Stock Information
Company Name: Neoleukin Therapeutics Inc.
Stock Symbol: NLTX
Market: NYSE
Menu
NLTX NLTX Quote NLTX Short NLTX News NLTX Articles NLTX Message Board
Get NLTX Alerts

News, Short Squeeze, Breakout and More Instantly...